Content
All Posts > Content under Healthcare
New Biogen CEO Reduces Potential For Takeout, Says Jefferies
Article By:
The Fly
Read
Tuesday, December 20, 2016 9:20 AM EDT
Biogen "likely looks to continue an independent course at least for now," Abrahams tells investors in a research note. He believes the company's shift from a leader with a more science-oriented background to an operational-focused CEO makes sense.
In this article: BIIB
Biotechs Fade Again In Late Day Sell-Off
Article By:
Rod Raynovich
Read
Monday, December 19, 2016 8:51 PM EDT
Biotech stocks got a jump-start this morning but peaked quickly then abruptly sold off at about 2p. The IBB ended down 1.33% to 268.79 off recent five-day highs of $274 and considerably off post-election highs of $293.
Clovis Jumps After Securing FDA Approval For Ovarian Cancer Drug
Article By:
The Fly
Read
Monday, December 19, 2016 5:18 PM EDT
Shares of Clovis Oncology are on the rise after the U.S. Food and Drug Administration granted accelerated approval to its rucaparib drug in advanced ovarian cancer, surprising the market, which was not expecting an announcement until February.
Weighing The Week Ahead: New Year, New Highs, And A New List Of Worries
Article By:
Jeff Miller
Read
Sunday, December 18, 2016 2:17 AM EDT
There is a normal dose of economic data this week, but we are entering a quiet, pre-holiday period. As the rally faltered a bit, the Dow 20K talk yielded to a discussion of what could go wrong.
Can GILD Stock Make A Comeback In 2017?
Article By:
Amigobulls
Read
Friday, December 16, 2016 2:20 PM EDT
Gilead stock seems well poised for an up move from current levels of about $75.5 per share. It has a current beta of 1.20 which means it is more volatile stock than the general stock market, but could well provide a good risk-adjusted return in 2017.
The FDA: Small-Cap Catalyst Or Small-Cap Killer?
Article By:
Paradigm Press
Read
Friday, December 16, 2016 9:37 AM EDT
This particular bureaucracy neither gives nor takes. Data do. If a drug works, the company that develops it will do well. If a drug doesn’t work, the company that develops it had better have a diversified pipeline.
High Beta Continues As Top ETF Factor
Article By:
Ron Rowland
Read
Wednesday, December 14, 2016 11:00 PM EDT
High Beta extends its run as the top-performing factor since February. Sector rotation out of Health Care ETFs persists as drugs and biotech submit to selling pressure, and North America provides the global leadership.
The Market’s Tale Of Two Fifth Avenues
Article By:
Michele Schneider
Read
Wednesday, December 14, 2016 9:13 PM EDT
Today, the Fed announced a 25 bps increase in rates with the expectation of 3 more raises in 2017. Afterwards, Fed Chair Janet Yellen, said the U.S. economic outlook is "highly uncertain."
In this article: IBB, IYT, KRE, SMH, XRT, IWM Also: QQQ, DIA, GDX, GLD, IYR, SLV, SPY, TAN, TLT, UUP
Express Scripts Slides As CEO Expects Pricing Scrutiny To Continue
Bill Ackman Cut His Valeant Stake; Will Bloodbath Ensue?
Article By:
Shock Exchange
Read
Wednesday, December 14, 2016 2:40 PM EDT
Pershing Square's Bill Ackman cut his VRX stake. Asset sales have not occurred and a Fed rate hike could dampen future sales. VRX's intrinsic value is less than $1. Bulls could follow the "smart money" and sell VRX en masse. Will a bloodbath ensue?
Cannabis Industry Should Benefit From The 21st Century Cures Act
Article By:
Jason Napodano
Read
Wednesday, December 14, 2016 1:38 PM EDT
The cannabis industry should benefit greatly from the passing of the Cures Act. The medical benefits of marijuana, or more specifically, cannabinoids, are real.
In this article: VBIO
Don’t Get Caught With These 5 Stocks Ahead Of Earnings Season - Wednesday Dec. 14
Article By:
Leigh Drogen
Read
Wednesday, December 14, 2016 10:47 AM EDT
With Q3 earnings season all but over, investors can rejoice in the gains that were reported during the quarter. Earnings and revenue came in higher than a year earlier with future estimates expected to build on this success.